A new paradigm in cancer treatment – combining the effectiveness of targeted therapy and immunotherapy

A new paradigm in cancer treatment – combining the effectiveness of targeted therapy and immunotherapy

Press Releases

02 November 2015Karus Therapeutics presenting at the EORTC-NCI-EMA-AACR Innovation and Biomarkers in Cancer Drug Development

Oxford, UK, 2 November 2015 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer, has announced that it will be giving a poster presentation at the EORTC-NCI-EMA-AACR Innovation and Biomarkers in Cancer Drug Development, Brussels, Belgium. The conference will take place in 2016.

The poster presentation is entitled “Design and Development of a Novel Series of PI3K-p110β/δ Inhibitors With Combined Tumor Immunotherapeutic, Growth Inhibition and Anti-Metastatic Activity”.

For more information on Karus’s presentations or for media enquiries, please contact karus@instinctif.com.